Our study is the first one to validate the association between XPG rs2296147 polymorphism and risk of CRC, previous studies focus on how this site act on the clinical outcome of platinum-based chemotherapy in NSCLC patients [19, 22, 23, 34, 35], susceptibility of prostate cancer patients [36, 37], gastric cancer [38, 39], and breast cancer [20], but the number was limited. This evidence concerns the gene ERCC5 and prostate carcinoma.